Silo Pharma (NASDAQ: SILO) shares are catching a bid, moving 16% higher to reach $6.39 on Tuesday. The move isn’t surprising; SILO is attracting the...
Mental health professionals turn to ketamine for treatment-resistant conditions. The post Ketamine Use Case Expands, But Concerns Persist appeared first...
The article Top Reasons To Be At Wonderland 2022 (Part 1) was originally published on Microdose. 2021 was a big year for the psychedelic medicine industry....
IntelGenx Corp. (IGX.TO) on Thursday provided an update on its collaboration with its strategic partner, Atai Life Sciences (atai) for the development...
Psychedelic medicines make headlines for indications like PTSD, depression, and anxiety, but they’re being studied for a much broader range of conditions. The...
The article Palo Santo Closes $50 Million Psychedelic Investment Fund was originally published on Microdose. Palo Santo Closes $50 Million Psychedelic...
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced...
Clairvoyant Therapeutics, a Canadian biotech company focused on the development of psychedelic drug therapies for the treatment of addiction, is pleased...
The article Breaking News: Compass Pathways to run TWO Phase 3 Trials for Depression was originally published on Microdose. Today, psychedelic medicine...
The article Convergence Partners Invests in Psychedelic CRO Clerkenwell Health was originally published on Microdose. Convergence Partners invests...